Lv1
78 积分 2025-10-12 加入
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials
18天前
已完结
Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases
19天前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
20天前
已完结
The role of COX-2 inhibitors in lung cancer COX-2
24天前
已完结
The next generation of immunotherapies for lung cancers
24天前
已完结
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
24天前
已完结
Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade
1个月前
已完结
Comparative efficacy of bone-modifying agents in the treatment of lung cancer bone metastases: immunotherapy era
2个月前
已完结
Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases
2个月前
已完结
Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays "cold" immune characteristics in Non-small cell lung cancer
2个月前
已完结
皖公网安备34019202002308
